Today: 21 May 2026
AST SpaceMobile stock pops on AT&T beta satellite-to-phone plan — what investors watch next
5 January 2026
2 mins read

AST SpaceMobile stock pops on AT&T beta satellite-to-phone plan — what investors watch next

New York, January 5, 2026, 12:53 (ET) — Regular session

  • AST SpaceMobile shares rose about 5% as investors digested fresh signs of commercialization and launch momentum.
  • AT&T said it plans a beta direct-to-device satellite service in the first half of 2026, with a broader rollout date still not set.
  • Traders are watching BlueBird 7 launch preparations and the next quarterly update calendar.

AST SpaceMobile shares climbed on Monday after AT&T said it plans to begin a beta “direct-to-device” satellite service in the first half of 2026 using AST’s network, a step investors have been waiting for as the company pushes toward commercial use. Light Reading

The update matters now because AST is trying to prove it can scale from a handful of spacecraft to a working constellation that supports paying users. The stock has tended to swing with each milestone that tightens the link between launch progress and revenue timing.

Direct-to-device, sometimes called “direct-to-cell,” is satellite connectivity that works with standard smartphones without special hardware. A carrier-backed beta is one of the first tests of whether the service can move beyond demonstrations into broader, day-to-day use. Light Reading

AT&T said the initial beta would be offered to a “select number” of consumer customers and FirstNet public safety users within the next six months, with a commercial launch to follow, Light Reading reported. An AT&T spokesperson said it was still too early to give a specific date for expanding beyond the beta phase. Light Reading

The carrier and AST are also building ground infrastructure. AT&T has deployed four “ground gateways” — the satellite dishes and network equipment that route signals between satellites and the carrier’s terrestrial network — but more are needed for broader service across the United States, the report said. Light Reading

On the space side, AST has started its launch campaign for the next-generation BlueBird satellites, which carry large antenna arrays designed to deliver 4G and 5G broadband from low Earth orbit, the band of space used by many communications satellites. After BlueBird 6 launched on Dec. 23, the next satellite, BlueBird 7, arrived in Florida for integration with its launch vehicle, Via Satellite reported.

AST is aiming for a steady cadence that investors see as the key to valuation. The company has targeted 45 to 60 satellites in orbit by the end of 2026 and has described launches every one to two months on average, according to the reports.

“BlueBird 6 is a breakthrough moment for AST SpaceMobile,” CEO Abel Avellan said in comments carried by Via Satellite. Via Satellite

AST shares were up 5.3% at $87.92 in midday trading, after moving between $81.22 and $90.72 earlier in the session.

Competition is also sharpening as U.S. carriers position for satellite-to-phone coverage. Light Reading pointed to T-Mobile’s partnership with SpaceX’s Starlink and Apple’s satellite messaging via Globalstar as benchmarks that keep pressure on rollout timelines.

But the upside case rests on execution. Any delay in launches, satellite deployment, or the buildout of gateways could push out service timelines and undermine the rollout narrative that has supported the stock’s recent volatility.

Next up, traders will look for updates on BlueBird 7 integration and any firmer timing on AT&T’s beta rollout, and they will watch the calendar for the company’s next quarterly update — Zacks lists March 2, 2026 as the next earnings report date.

Stock Market Today

  • Stocks Climb as Oil Prices and Treasury Yields Drop Ahead of Nvidia Earnings
    May 20, 2026, 6:04 PM EDT. U.S. stocks surged with the Dow Jones up 1.31%, S&P 500 gaining 1.08%, and Nasdaq rising 1.54% on May 20, 2026. This followed a sharp decline in oil prices, with WTI crude down 5.66% at $98.26 per barrel, and Brent crude falling 5.63%. Lower oil prices came after reports of progress in Middle East peace talks. Treasury yields eased, with the 10-year yield dropping over 9 basis points, alleviating recent inflation concerns. Market focus shifts to Nvidia's Q1 earnings report, seen as a critical indicator for the AI sector and chip demand. Nvidia shares rose over 1% ahead of results, trading near a 20% gain for the year. Analysts caution that while expectations are muted, the report could influence the broader market sentiment significantly.

Latest articles

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

20 May 2026
Xanadu Quantum Technologies’ shares surged 20.4% to $14.13 Wednesday, rebounding after a sharp May decline. The company reported Q1 revenue of $2.83 million and a net loss of $20.6 million, with 43.3 million Class B shares outstanding and a prospectus covering up to 293.7 million more. Other quantum stocks also rose. Xanadu is in talks for up to $285 million in Canadian government support.
MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
Lam Research stock jumps 6% as chip-tool rally builds on BofA AI call ahead of CES
Previous Story

Lam Research stock jumps 6% as chip-tool rally builds on BofA AI call ahead of CES

Nike stock climbs as BTIG tags $100 target, UBS sees stronger brand signals
Next Story

Nike stock climbs as BTIG tags $100 target, UBS sees stronger brand signals

Go toTop